GeoVax Engages Global Agencies for GEO-MVA Procurement in Multi-Billion Dollar Market
GeoVax's GEO-MVA vaccine candidate received EMA scientific advice enabling a single immunobridging trial as an expedited pathway and slated Phase 3 start in H2 2026. The company has begun engagement with global health and preparedness organizations targeting a potential multi-billion-dollar procurement market for mpox and smallpox stockpiles.
1. EMA Expedited Development Pathway
GeoVax secured scientific advice from the European Medicines Agency supporting an expedited development pathway for GEO-MVA based on a single immunobridging trial to a licensed MVA vaccine. This guidance affirms the program’s scientific foundation and allows for streamlined regulatory interactions ahead of pivotal studies.
2. Outreach to Health and Preparedness Organizations
The company has initiated discussions with global health agencies, national stockpile managers, and military preparedness programs to explore future procurement of its GEO-MVA vaccine. These engagements mark a shift from R&D toward commercialization planning and reflect growing confidence in the candidate’s potential.
3. Market Opportunity and Strategic Importance
Global demand for mpox and smallpox vaccines is projected to represent a multi-billion-dollar market driven by government stockpiling and international health mandates. GeoVax aims to diversify MVA supply, addressing the current reliance on a single manufacturer and enhancing biodefense readiness worldwide.